OTTAWA – In follow up to Health Canada’s communication on unauthorized stem cell therapies on May 15, 2019, Health Canada would like to clarify for patients and practitioners that Platelet Rich Plasma (PRP) treatments, including Platelet Rich Fibrin treatments, are not the same as cell therapies and, as a result, are not subject to Health Canada’s Policy Position Paper on Autologous Cell Therapy Products.
Tag: Clinical Trials
In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.